ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance

a Relative expressions of ATXN2L mRNA in 27 pairs of GC tissues and adjacent noncancerous tissues from The Cancer Genome Atlas dataset. b ATXN2L protein expressions by Western blot analysis in fresh GC tissues and paired noncancerous tissues. c Representative immunohistochemical staining of ATXN2L in different TNM stage GC tissues. d The frequency of high and low ATXN2L expressions in GC patients when categorized by TNM stages, recurrent patients of stage I–III and decedent of stage IV. The number of patients in each stage was noted in the bars. Higher ATXN2L level indicates e shorter overall survival in stage IV patients, as well as f shorter recurrence-free survival in stage I–III patients. g Kaplan-Meier analysis of stage I–III patient recurrence-free survival time by different TNM stages. Higher ATXN2L level indicates shorter recurrence-free survival in h stage I–II patients and i stage III patient